Iterum Therapeutics Gets FDA Approval Of Orlynvah
Iterum Therapeutics Shares Soar on FDA's Orlynvah Approval
The clinical-stage pharmaceutical company said Friday that the Food and Drug Administration has approved its new drug application for Orlynvah as a treatment for uncomplicated urinary tract infections caused by certain microorganisms in adult women with limited or no alternative oral antibacterial treatment options.
Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades--Company ...
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and ...
IterumTherapeutics今日宣布，美国FDA已批准其药品Orlynvah（sulopenem etzadroxil & ...
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and ...
都柏林和芝加哥 - Iterum Therapeutics plc (NASDAQ:ITRM) 今天宣布,美国食品和药物管理局(FDA)已批准其新药申请ORLYNVAH™(sulopenem etzadroxil和probenecid)。该药物适用于治疗成年女性的非复杂性尿路感染(uUTIs),特别是由大肠杆菌、肺炎克雷伯菌或奇异变形杆菌引起的感染。ORLYNVAH™是美国首个获批的口服青霉烯类抗 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback